According to a recent LinkedIn post from Circular Genomics, the company is drawing attention to a new peer‑reviewed publication in Nature Molecular Psychiatry. The post highlights research on a novel brain‑derived circular RNA (circRNA) biomarker associated with antidepressant response.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The publication, as described in the post, focuses on CDR1as, a brain‑derived circRNA regulated by 5‑HT2A and BDNF/TrkB signaling pathways. Baseline levels of this biomarker reportedly distinguished future responders from non‑responders to the SSRI sertraline with high accuracy.
The post suggests that this biomarker could help predict both response and remission to SSRIs, potentially addressing a major gap in personalized depression care. If successfully translated into clinical tools, such predictive capability could support Circular Genomics’ efforts to commercialize companion diagnostics or decision‑support tests in psychiatry.
From an investor perspective, peer‑reviewed validation in a high‑profile journal may strengthen the company’s scientific credibility and differentiation in the precision mental‑health market. This could enhance its ability to attract partnerships with pharmaceutical companies, secure reimbursement discussions, and raise capital for further clinical validation and regulatory pathways.
More broadly, the focus on reducing the trial‑and‑error nature of antidepressant selection aligns with healthcare trends toward personalization and cost efficiency. If Circular Genomics can scale this research into validated products, the work referenced in the post may represent an early signal of future revenue opportunities and competitive positioning in neuropsychiatric diagnostics.